Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT00990639

Effect of Candesartan in Alcoholic Liver Fibrosis

Beneficial Effect of Angiotensin-blocking Agent Candesartan on Alcoholic Liver Fibrosis: A Randomized Controlled Trial

Sponsor: Yonsei University

Interventions candesartan for hepatic fibrosis

Updated 5 times since 2017 Last updated: Oct 6, 2009 Started: Sep 30, 2005 Primary completion: Dec 31, 2008 Completion: Mar 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Alcoholic Liver Disease and is currently completed. Yonsei University leads this study, which shows 5 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Yonsei University

Data source: Yonsei University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Wŏnju, South Korea